<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="confer">
            <roleset id="confer.01" name="" wordnet="2">
                <roles>
                    <role n="0" descr="agent&#x09;&#x09;// mechanism, process, entity(imply to condition or property in that entity) // &#x0A;" />
                    <role n="1" descr="given biological property&#x09;&#x0A;" />
                    <role n="2" descr="entity receiving the biological property&#x09;         // gene product, celll, tissue, etc. //&#x0A;" />
                </roles>
                <example src="PERMUTATE" no="0">
                    <text>06-BG resistance in a tolC-deficient strain can be conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>06-BG resistance in a tolC-deficient strain has been conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>06-BG resistance in a tolC-deficient strain is able to be conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>06-BG resistance in a tolC-deficient strain is conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>06-BG resistance in a tolC-deficient strain may have been conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>06-BG resistance in a tolC-deficient strain was conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that Human 06-alkylguaning-DNA alkyltransferase are able to confer resistance to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that Human 06-alkylguaning-DNA alkyltransferase are believed to confer resistance to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that Human 06-alkylguaning-DNA alkyltransferase are observed to confer resistance to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that Human 06-alkylguaning-DNA alkyltransferase can confer resistance to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that Human 06-alkylguaning-DNA alkyltransferase confer resistance to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that Human 06-alkylguaning-DNA alkyltransferase conferred resistance to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that Human 06-alkylguaning-DNA alkyltransferase could confer resistance to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that Human 06-alkylguaning-DNA alkyltransferase have the ability to confer resistance to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that Human 06-alkylguaning-DNA alkyltransferase may confer resistance to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that Human 06-alkylguaning-DNA alkyltransferase may have conferred resistance to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that Human 06-alkylguaning-DNA alkyltransferase may have the ability to confer resistance to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that Human 06-alkylguaning-DNA alkyltransferase might confer resistance to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that Human 06-alkylguaning-DNA alkyltransferase were able to confer resistance to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that Human 06-alkylguaning-DNA alkyltransferase were believed to confer resistance to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that Human 06-alkylguaning-DNA alkyltransferase will confer resistance to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that Human 06-alkylguaning-DNA alkyltransferase would confer resistance to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that Human 06-alkylguaning-DNA alkyltransferase would have conferred resistance to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that The portion of the STATs are able to confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that The portion of the STATs are believed to confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that The portion of the STATs are observed to confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that The portion of the STATs can confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that The portion of the STATs confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that The portion of the STATs conferred specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that The portion of the STATs could confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that The portion of the STATs have the ability to confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that The portion of the STATs may confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that The portion of the STATs may have conferred specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that The portion of the STATs may have the ability to confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that The portion of the STATs might confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that The portion of the STATs were able to confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that The portion of the STATs were believed to confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that The portion of the STATs will confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that The portion of the STATs would confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that The portion of the STATs would have conferred specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance can be conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance can be conferred by transfection of AGT to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance can have been conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance can have been conferred by transfection of AGT to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance could be conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance could be conferred by transfection of AGT to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance has been able to be conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance has been able to be conferred by transfection of AGT to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance has been conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance has been conferred by transfection of AGT to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance is able to be conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance is able to be conferred by transfection of AGT to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance is believed to be conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance is believed to be conferred by transfection of AGT to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance is believed to have been conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance is believed to have been conferred by transfection of AGT to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance is conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance is conferred by transfection of AGT to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance is observed to be conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance is observed to be conferred by transfection of AGT to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance is shown to be conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance is shown to be conferred by transfection of AGT to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance may be conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance may be conferred by transfection of AGT to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance may have been conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance may have been conferred by transfection of AGT to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance might be conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance might be conferred by transfection of AGT to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance was able to be conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance was able to be conferred by transfection of AGT to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance was believed to be conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance was believed to be conferred by transfection of AGT to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance was conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance was conferred by transfection of AGT to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance was observed to be conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance was observed to be conferred by transfection of AGT to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance was shown to be conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance was shown to be conferred by transfection of AGT to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="78">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance will be conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="79">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance will be conferred by transfection of AGT to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="80">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance will have been conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="81">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance will have been conferred by transfection of AGT to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="82">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance would be conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="83">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance would be conferred by transfection of AGT to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="84">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that simply replacing the C-terminus with that of Stat5 are able to confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="85">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that simply replacing the C-terminus with that of Stat5 are believed to confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="86">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that simply replacing the C-terminus with that of Stat5 are observed to confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="87">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that simply replacing the C-terminus with that of Stat5 can confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="88">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that simply replacing the C-terminus with that of Stat5 confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="89">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that simply replacing the C-terminus with that of Stat5 conferred the Stat5 phenotype of stability in the presence of MG132 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="90">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that simply replacing the C-terminus with that of Stat5 could confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="91">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that simply replacing the C-terminus with that of Stat5 have the ability to confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="92">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that simply replacing the C-terminus with that of Stat5 may confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="93">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that simply replacing the C-terminus with that of Stat5 may have conferred the Stat5 phenotype of stability in the presence of MG132 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="94">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that simply replacing the C-terminus with that of Stat5 may have the ability to confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="95">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that simply replacing the C-terminus with that of Stat5 might confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="96">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that simply replacing the C-terminus with that of Stat5 were able to confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="97">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that simply replacing the C-terminus with that of Stat5 were believed to confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="98">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that simply replacing the C-terminus with that of Stat5 will confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="99">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that simply replacing the C-terminus with that of Stat5 would confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="100">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that simply replacing the C-terminus with that of Stat5 would have conferred the Stat5 phenotype of stability in the presence of MG132 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="101">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that specificity can be conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="102">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that specificity can have been conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="103">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that specificity could be conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="104">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that specificity has been able to be conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="105">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that specificity has been conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="106">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that specificity is able to be conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="107">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that specificity is believed to be conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="108">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that specificity is believed to have been conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="109">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that specificity is conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="110">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that specificity is observed to be conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="111">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that specificity is shown to be conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="112">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that specificity may be conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="113">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that specificity may have been conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="114">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that specificity might be conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="115">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that specificity was able to be conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="116">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that specificity was believed to be conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="117">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that specificity was conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="118">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that specificity was observed to be conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="119">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that specificity was shown to be conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="120">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that specificity will be conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="121">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that specificity will have been conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="122">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that specificity would be conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="123">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that the Stat5 phenotype of stability in the presence of MG132 can be conferred by simply replacing the C-terminus with that of Stat5 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="124">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that the Stat5 phenotype of stability in the presence of MG132 can have been conferred by simply replacing the C-terminus with that of Stat5 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="125">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that the Stat5 phenotype of stability in the presence of MG132 could be conferred by simply replacing the C-terminus with that of Stat5 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="126">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that the Stat5 phenotype of stability in the presence of MG132 has been able to be conferred by simply replacing the C-terminus with that of Stat5 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="127">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that the Stat5 phenotype of stability in the presence of MG132 has been conferred by simply replacing the C-terminus with that of Stat5 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="128">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that the Stat5 phenotype of stability in the presence of MG132 is able to be conferred by simply replacing the C-terminus with that of Stat5 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="129">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that the Stat5 phenotype of stability in the presence of MG132 is believed to be conferred by simply replacing the C-terminus with that of Stat5 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="130">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that the Stat5 phenotype of stability in the presence of MG132 is believed to have been conferred by simply replacing the C-terminus with that of Stat5 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="131">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that the Stat5 phenotype of stability in the presence of MG132 is conferred by simply replacing the C-terminus with that of Stat5 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="132">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that the Stat5 phenotype of stability in the presence of MG132 is observed to be conferred by simply replacing the C-terminus with that of Stat5 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="133">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that the Stat5 phenotype of stability in the presence of MG132 is shown to be conferred by simply replacing the C-terminus with that of Stat5 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="134">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that the Stat5 phenotype of stability in the presence of MG132 may be conferred by simply replacing the C-terminus with that of Stat5 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="135">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that the Stat5 phenotype of stability in the presence of MG132 may have been conferred by simply replacing the C-terminus with that of Stat5 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="136">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that the Stat5 phenotype of stability in the presence of MG132 might be conferred by simply replacing the C-terminus with that of Stat5 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="137">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that the Stat5 phenotype of stability in the presence of MG132 was able to be conferred by simply replacing the C-terminus with that of Stat5 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="138">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that the Stat5 phenotype of stability in the presence of MG132 was believed to be conferred by simply replacing the C-terminus with that of Stat5 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="139">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that the Stat5 phenotype of stability in the presence of MG132 was conferred by simply replacing the C-terminus with that of Stat5 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="140">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that the Stat5 phenotype of stability in the presence of MG132 was observed to be conferred by simply replacing the C-terminus with that of Stat5 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="141">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that the Stat5 phenotype of stability in the presence of MG132 was shown to be conferred by simply replacing the C-terminus with that of Stat5 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="142">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that the Stat5 phenotype of stability in the presence of MG132 will be conferred by simply replacing the C-terminus with that of Stat5 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="143">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that the Stat5 phenotype of stability in the presence of MG132 will have been conferred by simply replacing the C-terminus with that of Stat5 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="144">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that the Stat5 phenotype of stability in the presence of MG132 would be conferred by simply replacing the C-terminus with that of Stat5 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="145">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that transfection of AGT are able to confer resistance to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="146">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that transfection of AGT are believed to confer resistance to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="147">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that transfection of AGT are observed to confer resistance to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="148">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that transfection of AGT can confer resistance to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="149">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that transfection of AGT confer resistance to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="150">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that transfection of AGT conferred resistance to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="151">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that transfection of AGT could confer resistance to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="152">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that transfection of AGT have the ability to confer resistance to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="153">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that transfection of AGT may confer resistance to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="154">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that transfection of AGT may have conferred resistance to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="155">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that transfection of AGT may have the ability to confer resistance to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="156">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that transfection of AGT might confer resistance to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="157">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that transfection of AGT were able to confer resistance to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="158">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that transfection of AGT were believed to confer resistance to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="159">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that transfection of AGT will confer resistance to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="160">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that transfection of AGT would confer resistance to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="161">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that transfection of AGT would have conferred resistance to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="162">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests the ability of Human 06-alkylguaning-DNA alkyltransferase to confer resistance to alkylation chemotherapies through backbone distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="163">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests the ability of The portion of the STATs to confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) through backbone distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="164">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests the ability of simply replacing the C-terminus with that of Stat5 to confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 through backbone distortions.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="165">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests the ability of transfection of AGT to confer resistance to alkylation-sensitive cells through backbone distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="166">
                    <text>Human 06-alkylguaning-DNA alkyltransferase conferred resistance for alkylation chemotherapies.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="167">
                    <text>Human 06-alkylguaning-DNA alkyltransferase conferring resistance for alkylation chemotherapies has not been determined.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="168">
                    <text>Human 06-alkylguaning-DNA alkyltransferase confers resistance for alkylation chemotherapies.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="169">
                    <text>In addition, the gene variant can not confer an increased risk of diabetes in a tolC-deficient strain.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="170">
                    <text>In addition, the gene variant could not confer an increased risk of diabetes in a tolC-deficient strain.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="171">
                    <text>In addition, the gene variant did not confer an increased risk of diabetes in a tolC-deficient strain.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="172">
                    <text>In addition, the gene variant does not confer an increased risk of diabetes in a tolC-deficient strain.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="173">
                    <text>In addition, the gene variant has not confer an increased risk of diabetes in a tolC-deficient strain.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="174">
                    <text>In addition, the gene variant is not able to confer an increased risk of diabetes in a tolC-deficient strain.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="175">
                    <text>In addition, the gene variant may not confer an increased risk of diabetes in a tolC-deficient strain.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="176">
                    <text>In addition, the gene variant might not confer an increased risk of diabetes in a tolC-deficient strain.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="177">
                    <text>In addition, the gene variant was not able to confer an increased risk of diabetes in a tolC-deficient strain.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="178">
                    <text>In addition, the gene variant will not confer an increased risk of diabetes in a tolC-deficient strain.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="179">
                    <text>In addition, the gene variant would not confer an increased risk of diabetes in a tolC-deficient strain.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="180">
                    <text>In addition, these mutations can not confer 06-BG resistance in a tolC-deficient strain.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="181">
                    <text>In addition, these mutations could not confer 06-BG resistance in a tolC-deficient strain.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="182">
                    <text>In addition, these mutations did not confer 06-BG resistance in a tolC-deficient strain.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="183">
                    <text>In addition, these mutations does not confer 06-BG resistance in a tolC-deficient strain.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="184">
                    <text>In addition, these mutations has not confer 06-BG resistance in a tolC-deficient strain.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="185">
                    <text>In addition, these mutations is not able to confer 06-BG resistance in a tolC-deficient strain.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="186">
                    <text>In addition, these mutations may not confer 06-BG resistance in a tolC-deficient strain.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="187">
                    <text>In addition, these mutations might not confer 06-BG resistance in a tolC-deficient strain.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="188">
                    <text>In addition, these mutations was not able to confer 06-BG resistance in a tolC-deficient strain.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="189">
                    <text>In addition, these mutations will not confer 06-BG resistance in a tolC-deficient strain.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="190">
                    <text>In addition, these mutations would not confer 06-BG resistance in a tolC-deficient strain.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="191">
                    <text>In itself, 06-BG resistance cannot be conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="192">
                    <text>In itself, 06-BG resistance could not be conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="193">
                    <text>In itself, 06-BG resistance is believed not to be conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="194">
                    <text>In itself, 06-BG resistance is not able to be conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="195">
                    <text>In itself, 06-BG resistance is not conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="196">
                    <text>In itself, 06-BG resistance may not be conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="197">
                    <text>In itself, 06-BG resistance may not have been conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="198">
                    <text>In itself, 06-BG resistance might not be conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="199">
                    <text>In itself, 06-BG resistance was believed not to be conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="200">
                    <text>In itself, 06-BG resistance was not able to be conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="201">
                    <text>In itself, 06-BG resistance was not conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="202">
                    <text>In itself, 06-BG resistance will not be conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="203">
                    <text>In itself, 06-BG resistance will not have been conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="204">
                    <text>In itself, 06-BG resistance would not be conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="205">
                    <text>In itself, EvgA overexpression cannot confer resistance.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="206">
                    <text>In itself, EvgA overexpression cannot have conferred resistance.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="207">
                    <text>In itself, EvgA overexpression could not confer resistance.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="208">
                    <text>In itself, EvgA overexpression did not confer resistance.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="209">
                    <text>In itself, EvgA overexpression does not confer resistance.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="210">
                    <text>In itself, EvgA overexpression is believed not to confer resistance.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="211">
                    <text>In itself, EvgA overexpression is not able to confer resistance.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="212">
                    <text>In itself, EvgA overexpression may not confer resistance.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="213">
                    <text>In itself, EvgA overexpression may not have conferred resistance.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="214">
                    <text>In itself, EvgA overexpression might not confer resistance.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="215">
                    <text>In itself, EvgA overexpression was believed not to confer resistance.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="216">
                    <text>In itself, EvgA overexpression was not able to confer resistance.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="217">
                    <text>In itself, EvgA overexpression will not confer resistance.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="218">
                    <text>In itself, EvgA overexpression will not have conferred resistance.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="219">
                    <text>In itself, EvgA overexpression would not confer resistance.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="220">
                    <text>In itself, resistance cannot be conferred by EvgA overexpression.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="221">
                    <text>In itself, resistance could not be conferred by EvgA overexpression.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="222">
                    <text>In itself, resistance is believed not to be conferred by EvgA overexpression.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="223">
                    <text>In itself, resistance is not able to be conferred by EvgA overexpression.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="224">
                    <text>In itself, resistance is not conferred by EvgA overexpression.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="225">
                    <text>In itself, resistance may not be conferred by EvgA overexpression.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="226">
                    <text>In itself, resistance may not have been conferred by EvgA overexpression.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="227">
                    <text>In itself, resistance might not be conferred by EvgA overexpression.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="228">
                    <text>In itself, resistance was believed not to be conferred by EvgA overexpression.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="229">
                    <text>In itself, resistance was not able to be conferred by EvgA overexpression.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="230">
                    <text>In itself, resistance was not conferred by EvgA overexpression.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="231">
                    <text>In itself, resistance will not be conferred by EvgA overexpression.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="232">
                    <text>In itself, resistance will not have been conferred by EvgA overexpression.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="233">
                    <text>In itself, resistance would not be conferred by EvgA overexpression.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="234">
                    <text>In itself, these mutations cannot confer 06-BG resistance.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="235">
                    <text>In itself, these mutations cannot have conferred 06-BG resistance.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="236">
                    <text>In itself, these mutations could not confer 06-BG resistance.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="237">
                    <text>In itself, these mutations did not confer 06-BG resistance.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="238">
                    <text>In itself, these mutations does not confer 06-BG resistance.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="239">
                    <text>In itself, these mutations is believed not to confer 06-BG resistance.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="240">
                    <text>In itself, these mutations is not able to confer 06-BG resistance.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="241">
                    <text>In itself, these mutations may not confer 06-BG resistance.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="242">
                    <text>In itself, these mutations may not have conferred 06-BG resistance.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="243">
                    <text>In itself, these mutations might not confer 06-BG resistance.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="244">
                    <text>In itself, these mutations was believed not to confer 06-BG resistance.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="245">
                    <text>In itself, these mutations was not able to confer 06-BG resistance.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="246">
                    <text>In itself, these mutations will not confer 06-BG resistance.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="247">
                    <text>In itself, these mutations will not have conferred 06-BG resistance.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="248">
                    <text>In itself, these mutations would not confer 06-BG resistance.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="PERMUTATE" no="249">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and Human 06-alkylguaning-DNA alkyltransferase can confer resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="250">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and Human 06-alkylguaning-DNA alkyltransferase can have conferred resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="251">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and Human 06-alkylguaning-DNA alkyltransferase conferred resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="252">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and Human 06-alkylguaning-DNA alkyltransferase confers resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="253">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and Human 06-alkylguaning-DNA alkyltransferase could confer resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="254">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and Human 06-alkylguaning-DNA alkyltransferase has conferred resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="255">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and Human 06-alkylguaning-DNA alkyltransferase has the ability to confer resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="256">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and Human 06-alkylguaning-DNA alkyltransferase is able to confer resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="257">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and Human 06-alkylguaning-DNA alkyltransferase is believed to confer resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="258">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and Human 06-alkylguaning-DNA alkyltransferase is observed to confer resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="259">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and Human 06-alkylguaning-DNA alkyltransferase may confer resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="260">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and Human 06-alkylguaning-DNA alkyltransferase may have conferred resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="261">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and Human 06-alkylguaning-DNA alkyltransferase might confer resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="262">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and Human 06-alkylguaning-DNA alkyltransferase was able to confer resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="263">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and Human 06-alkylguaning-DNA alkyltransferase was believed to confer resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="264">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and Human 06-alkylguaning-DNA alkyltransferase was observed to confer resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="265">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and Human 06-alkylguaning-DNA alkyltransferase will confer resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="266">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and Human 06-alkylguaning-DNA alkyltransferase will have conferred resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="267">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and Human 06-alkylguaning-DNA alkyltransferase would confer resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="268">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance can be conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="269">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance can be conferred by substitutions at Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="270">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance can have been conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="271">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance can have been conferred by substitutions at Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="272">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance could be conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="273">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance could be conferred by substitutions at Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="274">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance has been conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="275">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance has been conferred by substitutions at Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="276">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is able to be conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="277">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is able to be conferred by substitutions at Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="278">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is believed to be conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="279">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is believed to be conferred by substitutions at Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="280">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="281">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is conferred by substitutions at Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="282">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance may be conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="283">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance may be conferred by substitutions at Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="284">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance may have been conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="285">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance may have been conferred by substitutions at Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="286">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance might be conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="287">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance might be conferred by substitutions at Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="288">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was able to be conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="289">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was able to be conferred by substitutions at Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="290">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was believed to be conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="291">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was believed to be conferred by substitutions at Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="292">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="293">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was conferred by substitutions at Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="294">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance will be conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="295">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance will be conferred by substitutions at Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="296">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance will have been conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="297">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance will have been conferred by substitutions at Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="298">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance would be conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="299">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance would be conferred by substitutions at Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="300">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and substitutions at Gly156 and Lys165 can confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="301">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and substitutions at Gly156 and Lys165 can have conferred resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="302">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and substitutions at Gly156 and Lys165 conferred resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="303">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and substitutions at Gly156 and Lys165 confers resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="304">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and substitutions at Gly156 and Lys165 could confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="305">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and substitutions at Gly156 and Lys165 has conferred resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="306">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and substitutions at Gly156 and Lys165 has the ability to confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="307">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and substitutions at Gly156 and Lys165 is able to confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="308">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and substitutions at Gly156 and Lys165 is believed to confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="309">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and substitutions at Gly156 and Lys165 is observed to confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="310">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and substitutions at Gly156 and Lys165 may confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="311">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and substitutions at Gly156 and Lys165 may have conferred resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="312">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and substitutions at Gly156 and Lys165 might confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="313">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and substitutions at Gly156 and Lys165 was able to confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="314">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and substitutions at Gly156 and Lys165 was believed to confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="315">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and substitutions at Gly156 and Lys165 was observed to confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="316">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and substitutions at Gly156 and Lys165 will confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="317">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and substitutions at Gly156 and Lys165 will have conferred resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="318">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and substitutions at Gly156 and Lys165 would confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="319">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and The portion of the STATs can confer resistance to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="320">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and The portion of the STATs can have conferred resistance to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="321">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and The portion of the STATs conferred resistance to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="322">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and The portion of the STATs confers resistance to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="323">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and The portion of the STATs could confer resistance to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="324">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and The portion of the STATs has conferred resistance to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="325">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and The portion of the STATs has the ability to confer resistance to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="326">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and The portion of the STATs is able to confer resistance to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="327">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and The portion of the STATs is believed to confer resistance to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="328">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and The portion of the STATs is observed to confer resistance to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="329">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and The portion of the STATs may confer resistance to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="330">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and The portion of the STATs may have conferred resistance to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="331">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and The portion of the STATs might confer resistance to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="332">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and The portion of the STATs was able to confer resistance to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="333">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and The portion of the STATs was believed to confer resistance to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="334">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and The portion of the STATs was observed to confer resistance to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="335">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and The portion of the STATs will confer resistance to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="336">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and The portion of the STATs will have conferred resistance to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="337">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and The portion of the STATs would confer resistance to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="338">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance can be conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="339">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance can have been conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="340">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance could be conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="341">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance has been conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="342">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is able to be conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="343">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is believed to be conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="344">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="345">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance may be conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="346">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance may have been conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="347">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance might be conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="348">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was able to be conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="349">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was believed to be conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="350">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="351">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance will be conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="352">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance will have been conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="353">
                    <text>Increased AGT levels parallel acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance would be conferred by The portion of the STATs to either a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="354">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance can be conferred by simply replacing the C-terminus with that of Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="355">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance can have been conferred by simply replacing the C-terminus with that of Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="356">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance could be conferred by simply replacing the C-terminus with that of Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="357">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance has been conferred by simply replacing the C-terminus with that of Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="358">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is able to be conferred by simply replacing the C-terminus with that of Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="359">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is believed to be conferred by simply replacing the C-terminus with that of Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="360">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is conferred by simply replacing the C-terminus with that of Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="361">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance may be conferred by simply replacing the C-terminus with that of Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="362">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance may have been conferred by simply replacing the C-terminus with that of Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="363">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance might be conferred by simply replacing the C-terminus with that of Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="364">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was able to be conferred by simply replacing the C-terminus with that of Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="365">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was believed to be conferred by simply replacing the C-terminus with that of Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="366">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was conferred by simply replacing the C-terminus with that of Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="367">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance will be conferred by simply replacing the C-terminus with that of Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="368">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance will have been conferred by simply replacing the C-terminus with that of Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="369">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance would be conferred by simply replacing the C-terminus with that of Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="370">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and simply replacing the C-terminus with that of Stat5 can confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="371">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and simply replacing the C-terminus with that of Stat5 can have conferred resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="372">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and simply replacing the C-terminus with that of Stat5 conferred resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="373">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and simply replacing the C-terminus with that of Stat5 confers resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="374">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and simply replacing the C-terminus with that of Stat5 could confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="375">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and simply replacing the C-terminus with that of Stat5 has conferred resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="376">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and simply replacing the C-terminus with that of Stat5 has the ability to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="377">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and simply replacing the C-terminus with that of Stat5 is able to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="378">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and simply replacing the C-terminus with that of Stat5 is believed to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="379">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and simply replacing the C-terminus with that of Stat5 is observed to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="380">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and simply replacing the C-terminus with that of Stat5 may confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="381">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and simply replacing the C-terminus with that of Stat5 may have conferred resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="382">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and simply replacing the C-terminus with that of Stat5 might confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="383">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and simply replacing the C-terminus with that of Stat5 was able to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="384">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and simply replacing the C-terminus with that of Stat5 was believed to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="385">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and simply replacing the C-terminus with that of Stat5 was observed to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="386">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and simply replacing the C-terminus with that of Stat5 will confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="387">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and simply replacing the C-terminus with that of Stat5 will have conferred resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="388">
                    <text>Increased AGT levels parallel acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and simply replacing the C-terminus with that of Stat5 would confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="389">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), EvgA overexpression can confer the resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="390">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), EvgA overexpression confer the resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="391">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), EvgA overexpression conferred the resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="392">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), EvgA overexpression could confer the resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="393">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), EvgA overexpression have conferred the resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="394">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), EvgA overexpression is able to confer the resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="395">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), EvgA overexpression is believed to confer the resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="396">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), EvgA overexpression may confer the resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="397">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), EvgA overexpression might confer the resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="398">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), EvgA overexpression was able to confer the resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="399">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), EvgA overexpression was believed to confer the resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="400">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), EvgA overexpression will confer the resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="401">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), EvgA overexpression would confer the resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="402">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), explaining the an increased risk of diabetes conferred by the gene variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="403">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), explaining the resistance conferred by EvgA overexpression (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="404">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the an increased risk of diabetes can be conferred by the gene variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="405">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the an increased risk of diabetes could be conferred by the gene variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="406">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the an increased risk of diabetes has been conferred by the gene variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="407">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the an increased risk of diabetes is able to be conferred by the gene variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="408">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the an increased risk of diabetes is believed to be conferred by the gene variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="409">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the an increased risk of diabetes is conferred by the gene variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="410">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the an increased risk of diabetes may be conferred by the gene variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="411">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the an increased risk of diabetes might be conferred by the gene variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="412">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the an increased risk of diabetes was able to be conferred by the gene variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="413">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the an increased risk of diabetes was believed to be conferred by the gene variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="414">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the an increased risk of diabetes was conferred by the gene variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="415">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the an increased risk of diabetes will be conferred by the gene variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="416">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the an increased risk of diabetes would be conferred by the gene variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="417">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the gene variant can confer the an increased risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="418">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the gene variant confer the an increased risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="419">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the gene variant conferred the an increased risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="420">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the gene variant could confer the an increased risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="421">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the gene variant have conferred the an increased risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="422">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the gene variant is able to confer the an increased risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="423">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the gene variant is believed to confer the an increased risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="424">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the gene variant may confer the an increased risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="425">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the gene variant might confer the an increased risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="426">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the gene variant was able to confer the an increased risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="427">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the gene variant was believed to confer the an increased risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="428">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the gene variant will confer the an increased risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="429">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the gene variant would confer the an increased risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="430">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance can be conferred by EvgA overexpression (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="431">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance could be conferred by EvgA overexpression (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="432">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance has been conferred by EvgA overexpression (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="433">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance is able to be conferred by EvgA overexpression (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="434">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance is believed to be conferred by EvgA overexpression (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="435">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance is conferred by EvgA overexpression (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="436">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance may be conferred by EvgA overexpression (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="437">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance might be conferred by EvgA overexpression (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="438">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance was able to be conferred by EvgA overexpression (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="439">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance was believed to be conferred by EvgA overexpression (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="440">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance was conferred by EvgA overexpression (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="441">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance will be conferred by EvgA overexpression (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="442">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance would be conferred by EvgA overexpression (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="443">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in 06-BG, since resistance can be conferred on Stat1 by substitutions at Gly156 and Lys165.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="444">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in 06-BG, since resistance can have been conferred on Stat1 by substitutions at Gly156 and Lys165.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="445">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in 06-BG, since resistance could be conferred on Stat1 by substitutions at Gly156 and Lys165.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="446">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in 06-BG, since resistance is able to be conferred on Stat1 by substitutions at Gly156 and Lys165.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="447">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in 06-BG, since substitutions at Gly156 and Lys165 can confer resistance on Stat1.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="448">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in 06-BG, since substitutions at Gly156 and Lys165 could confer resistance on Stat1.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="449">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in 06-BG, since substitutions at Gly156 and Lys165 has the ability to confer resistance on Stat1.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="450">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in 06-BG, since substitutions at Gly156 and Lys165 is able to confer resistance on Stat1.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="451">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in 06-BG, since substitutions at Gly156 and Lys165 is believed to confer resistance on Stat1.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="452">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in 06-BG, since substitutions at Gly156 and Lys165 may confer resistance on Stat1.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="453">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in 06-BG, since substitutions at Gly156 and Lys165 was able to confer resistance on Stat1.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="454">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in 06-BG, since substitutions at Gly156 and Lys165 will confer resistance on Stat1.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="455">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation chemotherapies, since Human 06-alkylguaning-DNA alkyltransferase can confer resistance on Stat1.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="456">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation chemotherapies, since Human 06-alkylguaning-DNA alkyltransferase could confer resistance on Stat1.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="457">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation chemotherapies, since Human 06-alkylguaning-DNA alkyltransferase has the ability to confer resistance on Stat1.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="458">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation chemotherapies, since Human 06-alkylguaning-DNA alkyltransferase is able to confer resistance on Stat1.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="459">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation chemotherapies, since Human 06-alkylguaning-DNA alkyltransferase is believed to confer resistance on Stat1.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="460">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation chemotherapies, since Human 06-alkylguaning-DNA alkyltransferase may confer resistance on Stat1.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="461">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation chemotherapies, since Human 06-alkylguaning-DNA alkyltransferase was able to confer resistance on Stat1.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="462">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation chemotherapies, since Human 06-alkylguaning-DNA alkyltransferase will confer resistance on Stat1.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="463">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation chemotherapies, since resistance can be conferred on Stat1 by Human 06-alkylguaning-DNA alkyltransferase.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="464">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation chemotherapies, since resistance can have been conferred on Stat1 by Human 06-alkylguaning-DNA alkyltransferase.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="465">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation chemotherapies, since resistance could be conferred on Stat1 by Human 06-alkylguaning-DNA alkyltransferase.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="466">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation chemotherapies, since resistance is able to be conferred on Stat1 by Human 06-alkylguaning-DNA alkyltransferase.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="467">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells, since resistance can be conferred on Stat1 by transfection of AGT.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="468">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells, since resistance can have been conferred on Stat1 by transfection of AGT.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="469">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells, since resistance could be conferred on Stat1 by transfection of AGT.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="470">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells, since resistance is able to be conferred on Stat1 by transfection of AGT.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="471">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells, since transfection of AGT can confer resistance on Stat1.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="472">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells, since transfection of AGT could confer resistance on Stat1.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="473">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells, since transfection of AGT has the ability to confer resistance on Stat1.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="474">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells, since transfection of AGT is able to confer resistance on Stat1.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="475">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells, since transfection of AGT is believed to confer resistance on Stat1.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="476">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells, since transfection of AGT may confer resistance on Stat1.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="477">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells, since transfection of AGT was able to confer resistance on Stat1.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="478">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells, since transfection of AGT will confer resistance on Stat1.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="479">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in either a MAPK or a MAPK substrate kinase (MAPKAP), since The portion of the STATs can confer specificity on Stat1.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="480">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in either a MAPK or a MAPK substrate kinase (MAPKAP), since The portion of the STATs could confer specificity on Stat1.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="481">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in either a MAPK or a MAPK substrate kinase (MAPKAP), since The portion of the STATs has the ability to confer specificity on Stat1.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="482">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in either a MAPK or a MAPK substrate kinase (MAPKAP), since The portion of the STATs is able to confer specificity on Stat1.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="483">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in either a MAPK or a MAPK substrate kinase (MAPKAP), since The portion of the STATs is believed to confer specificity on Stat1.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="484">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in either a MAPK or a MAPK substrate kinase (MAPKAP), since The portion of the STATs may confer specificity on Stat1.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="485">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in either a MAPK or a MAPK substrate kinase (MAPKAP), since The portion of the STATs was able to confer specificity on Stat1.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="486">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in either a MAPK or a MAPK substrate kinase (MAPKAP), since The portion of the STATs will confer specificity on Stat1.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="487">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in either a MAPK or a MAPK substrate kinase (MAPKAP), since specificity can be conferred on Stat1 by The portion of the STATs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="488">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in either a MAPK or a MAPK substrate kinase (MAPKAP), since specificity can have been conferred on Stat1 by The portion of the STATs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="489">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in either a MAPK or a MAPK substrate kinase (MAPKAP), since specificity could be conferred on Stat1 by The portion of the STATs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="490">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in either a MAPK or a MAPK substrate kinase (MAPKAP), since specificity is able to be conferred on Stat1 by The portion of the STATs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="491">
                    <text>The portion of the STATs (AGT) conferring specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) is therefore an active anticancer drug target.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="492">
                    <text>The portion of the STATs (AGT) having conferred specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) was therefore an active anticancer drug target.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="493">
                    <text>The portion of the STATs (AGT) that conferred specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) was therefore an active anticancer drug target.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="494">
                    <text>The portion of the STATs (AGT) that confers specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) is therefore an active anticancer drug target.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="495">
                    <text>The portion of the STATs (AGT) that has conferred specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) was therefore an active anticancer drug target.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="496">
                    <text>The portion of the STATs (AGT) which can confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) was therefore an active anticancer drug target.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="497">
                    <text>The portion of the STATs (AGT) which conferred specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) was therefore an active anticancer drug target.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="498">
                    <text>The portion of the STATs (AGT) which confers specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) is therefore an active anticancer drug target.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="499">
                    <text>The portion of the STATs (AGT) which has conferred specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) was therefore an active anticancer drug target.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="500">
                    <text>The portion of the STATs (AGT) which is able to confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) was therefore an active anticancer drug target.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="501">
                    <text>The portion of the STATs (AGT) which is believed to confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) was therefore an active anticancer drug target.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="502">
                    <text>The portion of the STATs (AGT) which is observed to confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) was therefore an active anticancer drug target.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="503">
                    <text>The portion of the STATs (AGT) which may confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) was therefore an active anticancer drug target.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="504">
                    <text>The portion of the STATs (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, can confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) and is therefore an active anticancer drug target.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="505">
                    <text>The portion of the STATs (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, conferred specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) and is therefore an active anticancer drug target.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="506">
                    <text>The portion of the STATs (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, confers specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) and is therefore an active anticancer drug target.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="507">
                    <text>The portion of the STATs (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, could confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) and was therefore an active anticancer drug target.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="508">
                    <text>The portion of the STATs (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, has the ability to confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) and is therefore an active anticancer drug target.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="509">
                    <text>The portion of the STATs (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, is able to confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) and is therefore an active anticancer drug target.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="510">
                    <text>The portion of the STATs (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, is believed to confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) and is therefore an active anticancer drug target.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="511">
                    <text>The portion of the STATs (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, is observed to confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) and is therefore an active anticancer drug target.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="512">
                    <text>The portion of the STATs (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, may confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) and is therefore an active anticancer drug target.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="513">
                    <text>The portion of the STATs (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, might confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) and was therefore an active anticancer drug target.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="514">
                    <text>The portion of the STATs (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, was able to confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) and was therefore an active anticancer drug target.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="515">
                    <text>The portion of the STATs (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, was believed to confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) and was therefore an active anticancer drug target.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="516">
                    <text>The portion of the STATs (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, was observed to confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) and was therefore an active anticancer drug target.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="517">
                    <text>The portion of the STATs (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, will confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) and is therefore an active anticancer drug target.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="518">
                    <text>The portion of the STATs (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, would confer specificity to either a MAPK or a MAPK substrate kinase (MAPKAP) and was therefore an active anticancer drug target.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="519">
                    <text>an increased risk of diabetes in a tolC-deficient strain can be conferred by the gene variant.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="520">
                    <text>an increased risk of diabetes in a tolC-deficient strain has been conferred by the gene variant.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="521">
                    <text>an increased risk of diabetes in a tolC-deficient strain is able to be conferred by the gene variant.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="522">
                    <text>an increased risk of diabetes in a tolC-deficient strain is conferred by the gene variant.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="523">
                    <text>an increased risk of diabetes in a tolC-deficient strain may have been conferred by the gene variant.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="524">
                    <text>an increased risk of diabetes in a tolC-deficient strain was conferred by the gene variant.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="525">
                    <text>simply replacing the C-terminus with that of Stat5 (AGT) conferring the Stat5 phenotype of stability in the presence of MG132 to Stat1 is therefore an active anticancer drug target.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="526">
                    <text>simply replacing the C-terminus with that of Stat5 (AGT) having conferred the Stat5 phenotype of stability in the presence of MG132 to Stat1 was therefore an active anticancer drug target.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="527">
                    <text>simply replacing the C-terminus with that of Stat5 (AGT) that conferred the Stat5 phenotype of stability in the presence of MG132 to Stat1 was therefore an active anticancer drug target.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="528">
                    <text>simply replacing the C-terminus with that of Stat5 (AGT) that confers the Stat5 phenotype of stability in the presence of MG132 to Stat1 is therefore an active anticancer drug target.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="529">
                    <text>simply replacing the C-terminus with that of Stat5 (AGT) that has conferred the Stat5 phenotype of stability in the presence of MG132 to Stat1 was therefore an active anticancer drug target.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="530">
                    <text>simply replacing the C-terminus with that of Stat5 (AGT) which can confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 was therefore an active anticancer drug target.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="531">
                    <text>simply replacing the C-terminus with that of Stat5 (AGT) which conferred the Stat5 phenotype of stability in the presence of MG132 to Stat1 was therefore an active anticancer drug target.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="532">
                    <text>simply replacing the C-terminus with that of Stat5 (AGT) which confers the Stat5 phenotype of stability in the presence of MG132 to Stat1 is therefore an active anticancer drug target.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="533">
                    <text>simply replacing the C-terminus with that of Stat5 (AGT) which has conferred the Stat5 phenotype of stability in the presence of MG132 to Stat1 was therefore an active anticancer drug target.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="534">
                    <text>simply replacing the C-terminus with that of Stat5 (AGT) which is able to confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 was therefore an active anticancer drug target.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="535">
                    <text>simply replacing the C-terminus with that of Stat5 (AGT) which is believed to confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 was therefore an active anticancer drug target.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="536">
                    <text>simply replacing the C-terminus with that of Stat5 (AGT) which is observed to confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 was therefore an active anticancer drug target.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="537">
                    <text>simply replacing the C-terminus with that of Stat5 (AGT) which may confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 was therefore an active anticancer drug target.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="538">
                    <text>simply replacing the C-terminus with that of Stat5 (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, can confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 and is therefore an active anticancer drug target.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="539">
                    <text>simply replacing the C-terminus with that of Stat5 (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, conferred the Stat5 phenotype of stability in the presence of MG132 to Stat1 and is therefore an active anticancer drug target.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="540">
                    <text>simply replacing the C-terminus with that of Stat5 (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, confers the Stat5 phenotype of stability in the presence of MG132 to Stat1 and is therefore an active anticancer drug target.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="541">
                    <text>simply replacing the C-terminus with that of Stat5 (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, could confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 and was therefore an active anticancer drug target.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="542">
                    <text>simply replacing the C-terminus with that of Stat5 (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, has the ability to confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 and is therefore an active anticancer drug target.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="543">
                    <text>simply replacing the C-terminus with that of Stat5 (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, is able to confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 and is therefore an active anticancer drug target.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="544">
                    <text>simply replacing the C-terminus with that of Stat5 (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, is believed to confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 and is therefore an active anticancer drug target.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="545">
                    <text>simply replacing the C-terminus with that of Stat5 (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, is observed to confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 and is therefore an active anticancer drug target.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="546">
                    <text>simply replacing the C-terminus with that of Stat5 (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, may confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 and is therefore an active anticancer drug target.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="547">
                    <text>simply replacing the C-terminus with that of Stat5 (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, might confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 and was therefore an active anticancer drug target.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="548">
                    <text>simply replacing the C-terminus with that of Stat5 (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, was able to confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 and was therefore an active anticancer drug target.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="549">
                    <text>simply replacing the C-terminus with that of Stat5 (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, was believed to confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 and was therefore an active anticancer drug target.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="550">
                    <text>simply replacing the C-terminus with that of Stat5 (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, was observed to confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 and was therefore an active anticancer drug target.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="551">
                    <text>simply replacing the C-terminus with that of Stat5 (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, will confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 and is therefore an active anticancer drug target.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="552">
                    <text>simply replacing the C-terminus with that of Stat5 (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, would confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 and was therefore an active anticancer drug target.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="553">
                    <text>simply replacing the C-terminus with that of Stat5 conferred the Stat5 phenotype of stability in the presence of MG132 for Stat1.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="554">
                    <text>simply replacing the C-terminus with that of Stat5 conferring the Stat5 phenotype of stability in the presence of MG132 for Stat1 has not been determined.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="555">
                    <text>simply replacing the C-terminus with that of Stat5 confers the Stat5 phenotype of stability in the presence of MG132 for Stat1.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="556">
                    <text>substitutions at Gly156 and Lys165 (AGT) conferring resistance to 06-BG is therefore an active anticancer drug target.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="557">
                    <text>substitutions at Gly156 and Lys165 (AGT) having conferred resistance to 06-BG was therefore an active anticancer drug target.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="558">
                    <text>substitutions at Gly156 and Lys165 (AGT) that conferred resistance to 06-BG was therefore an active anticancer drug target.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="559">
                    <text>substitutions at Gly156 and Lys165 (AGT) that confers resistance to 06-BG is therefore an active anticancer drug target.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="560">
                    <text>substitutions at Gly156 and Lys165 (AGT) that has conferred resistance to 06-BG was therefore an active anticancer drug target.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="561">
                    <text>substitutions at Gly156 and Lys165 (AGT) which can confer resistance to 06-BG was therefore an active anticancer drug target.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="562">
                    <text>substitutions at Gly156 and Lys165 (AGT) which conferred resistance to 06-BG was therefore an active anticancer drug target.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="563">
                    <text>substitutions at Gly156 and Lys165 (AGT) which confers resistance to 06-BG is therefore an active anticancer drug target.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="564">
                    <text>substitutions at Gly156 and Lys165 (AGT) which has conferred resistance to 06-BG was therefore an active anticancer drug target.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="565">
                    <text>substitutions at Gly156 and Lys165 (AGT) which is able to confer resistance to 06-BG was therefore an active anticancer drug target.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="566">
                    <text>substitutions at Gly156 and Lys165 (AGT) which is believed to confer resistance to 06-BG was therefore an active anticancer drug target.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="567">
                    <text>substitutions at Gly156 and Lys165 (AGT) which is observed to confer resistance to 06-BG was therefore an active anticancer drug target.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="568">
                    <text>substitutions at Gly156 and Lys165 (AGT) which may confer resistance to 06-BG was therefore an active anticancer drug target.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="569">
                    <text>substitutions at Gly156 and Lys165 (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, can confer resistance to 06-BG and is therefore an active anticancer drug target.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="570">
                    <text>substitutions at Gly156 and Lys165 (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, conferred resistance to 06-BG and is therefore an active anticancer drug target.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="571">
                    <text>substitutions at Gly156 and Lys165 (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, confers resistance to 06-BG and is therefore an active anticancer drug target.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="572">
                    <text>substitutions at Gly156 and Lys165 (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, could confer resistance to 06-BG and was therefore an active anticancer drug target.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="573">
                    <text>substitutions at Gly156 and Lys165 (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, has the ability to confer resistance to 06-BG and is therefore an active anticancer drug target.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="574">
                    <text>substitutions at Gly156 and Lys165 (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, is able to confer resistance to 06-BG and is therefore an active anticancer drug target.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="575">
                    <text>substitutions at Gly156 and Lys165 (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, is believed to confer resistance to 06-BG and is therefore an active anticancer drug target.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="576">
                    <text>substitutions at Gly156 and Lys165 (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, is observed to confer resistance to 06-BG and is therefore an active anticancer drug target.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="577">
                    <text>substitutions at Gly156 and Lys165 (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, may confer resistance to 06-BG and is therefore an active anticancer drug target.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="578">
                    <text>substitutions at Gly156 and Lys165 (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, might confer resistance to 06-BG and was therefore an active anticancer drug target.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="579">
                    <text>substitutions at Gly156 and Lys165 (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, was able to confer resistance to 06-BG and was therefore an active anticancer drug target.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="580">
                    <text>substitutions at Gly156 and Lys165 (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, was believed to confer resistance to 06-BG and was therefore an active anticancer drug target.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="581">
                    <text>substitutions at Gly156 and Lys165 (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, was observed to confer resistance to 06-BG and was therefore an active anticancer drug target.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="582">
                    <text>substitutions at Gly156 and Lys165 (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, will confer resistance to 06-BG and is therefore an active anticancer drug target.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="583">
                    <text>substitutions at Gly156 and Lys165 (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, would confer resistance to 06-BG and was therefore an active anticancer drug target.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="584">
                    <text>substitutions at Gly156 and Lys165 conferred resistance for 06-BG.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="585">
                    <text>substitutions at Gly156 and Lys165 conferring resistance for 06-BG has not been determined.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="586">
                    <text>substitutions at Gly156 and Lys165 confers resistance for 06-BG.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="587">
                    <text>transfection of AGT (AGT) conferring resistance to alkylation-sensitive cells is therefore an active anticancer drug target.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="588">
                    <text>transfection of AGT (AGT) having conferred resistance to alkylation-sensitive cells was therefore an active anticancer drug target.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="589">
                    <text>transfection of AGT (AGT) that conferred resistance to alkylation-sensitive cells was therefore an active anticancer drug target.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="590">
                    <text>transfection of AGT (AGT) that confers resistance to alkylation-sensitive cells is therefore an active anticancer drug target.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="591">
                    <text>transfection of AGT (AGT) that has conferred resistance to alkylation-sensitive cells was therefore an active anticancer drug target.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="592">
                    <text>transfection of AGT (AGT) which can confer resistance to alkylation-sensitive cells was therefore an active anticancer drug target.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="593">
                    <text>transfection of AGT (AGT) which conferred resistance to alkylation-sensitive cells was therefore an active anticancer drug target.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="594">
                    <text>transfection of AGT (AGT) which confers resistance to alkylation-sensitive cells is therefore an active anticancer drug target.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="595">
                    <text>transfection of AGT (AGT) which has conferred resistance to alkylation-sensitive cells was therefore an active anticancer drug target.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="596">
                    <text>transfection of AGT (AGT) which is able to confer resistance to alkylation-sensitive cells was therefore an active anticancer drug target.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="597">
                    <text>transfection of AGT (AGT) which is believed to confer resistance to alkylation-sensitive cells was therefore an active anticancer drug target.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="598">
                    <text>transfection of AGT (AGT) which is observed to confer resistance to alkylation-sensitive cells was therefore an active anticancer drug target.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="599">
                    <text>transfection of AGT (AGT) which may confer resistance to alkylation-sensitive cells was therefore an active anticancer drug target.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="600">
                    <text>transfection of AGT (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, can confer resistance to alkylation-sensitive cells and is therefore an active anticancer drug target.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="601">
                    <text>transfection of AGT (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, conferred resistance to alkylation-sensitive cells and is therefore an active anticancer drug target.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="602">
                    <text>transfection of AGT (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, confers resistance to alkylation-sensitive cells and is therefore an active anticancer drug target.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="603">
                    <text>transfection of AGT (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, could confer resistance to alkylation-sensitive cells and was therefore an active anticancer drug target.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="604">
                    <text>transfection of AGT (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, has the ability to confer resistance to alkylation-sensitive cells and is therefore an active anticancer drug target.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="605">
                    <text>transfection of AGT (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, is able to confer resistance to alkylation-sensitive cells and is therefore an active anticancer drug target.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="606">
                    <text>transfection of AGT (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, is believed to confer resistance to alkylation-sensitive cells and is therefore an active anticancer drug target.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="607">
                    <text>transfection of AGT (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, is observed to confer resistance to alkylation-sensitive cells and is therefore an active anticancer drug target.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="608">
                    <text>transfection of AGT (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, may confer resistance to alkylation-sensitive cells and is therefore an active anticancer drug target.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="609">
                    <text>transfection of AGT (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, might confer resistance to alkylation-sensitive cells and was therefore an active anticancer drug target.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="610">
                    <text>transfection of AGT (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, was able to confer resistance to alkylation-sensitive cells and was therefore an active anticancer drug target.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="611">
                    <text>transfection of AGT (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, was believed to confer resistance to alkylation-sensitive cells and was therefore an active anticancer drug target.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="612">
                    <text>transfection of AGT (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, was observed to confer resistance to alkylation-sensitive cells and was therefore an active anticancer drug target.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="613">
                    <text>transfection of AGT (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, will confer resistance to alkylation-sensitive cells and is therefore an active anticancer drug target.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="614">
                    <text>transfection of AGT (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, would confer resistance to alkylation-sensitive cells and was therefore an active anticancer drug target.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="615">
                    <text>transfection of AGT conferred resistance for alkylation-sensitive cells.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="616">
                    <text>transfection of AGT conferring resistance for alkylation-sensitive cells has not been determined.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="617">
                    <text>transfection of AGT confers resistance for alkylation-sensitive cells.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>In addition, nonsense or frameshift alterations in the coding sequence or by splice variants can not confer loss-of-function mutations in a tolC-deficient strain.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>In addition, nonsense or frameshift alterations in the coding sequence or by splice variants could not confer loss-of-function mutations in a tolC-deficient strain.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>In addition, nonsense or frameshift alterations in the coding sequence or by splice variants did not confer loss-of-function mutations in a tolC-deficient strain.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>In addition, nonsense or frameshift alterations in the coding sequence or by splice variants does not confer loss-of-function mutations in a tolC-deficient strain.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>In addition, nonsense or frameshift alterations in the coding sequence or by splice variants has not confer loss-of-function mutations in a tolC-deficient strain.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>In addition, nonsense or frameshift alterations in the coding sequence or by splice variants is not able to confer loss-of-function mutations in a tolC-deficient strain.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>In addition, nonsense or frameshift alterations in the coding sequence or by splice variants may not confer loss-of-function mutations in a tolC-deficient strain.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>In addition, nonsense or frameshift alterations in the coding sequence or by splice variants might not confer loss-of-function mutations in a tolC-deficient strain.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>In addition, nonsense or frameshift alterations in the coding sequence or by splice variants was not able to confer loss-of-function mutations in a tolC-deficient strain.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>In addition, nonsense or frameshift alterations in the coding sequence or by splice variants will not confer loss-of-function mutations in a tolC-deficient strain.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>In addition, nonsense or frameshift alterations in the coding sequence or by splice variants would not confer loss-of-function mutations in a tolC-deficient strain.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>In itself, loss-of-function mutations cannot be conferred by nonsense or frameshift alterations in the coding sequence or by splice variants.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>In itself, loss-of-function mutations could not be conferred by nonsense or frameshift alterations in the coding sequence or by splice variants.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>In itself, loss-of-function mutations is believed not to be conferred by nonsense or frameshift alterations in the coding sequence or by splice variants.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>In itself, loss-of-function mutations is not able to be conferred by nonsense or frameshift alterations in the coding sequence or by splice variants.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>In itself, loss-of-function mutations is not conferred by nonsense or frameshift alterations in the coding sequence or by splice variants.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>In itself, loss-of-function mutations may not be conferred by nonsense or frameshift alterations in the coding sequence or by splice variants.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>In itself, loss-of-function mutations may not have been conferred by nonsense or frameshift alterations in the coding sequence or by splice variants.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>In itself, loss-of-function mutations might not be conferred by nonsense or frameshift alterations in the coding sequence or by splice variants.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>In itself, loss-of-function mutations was believed not to be conferred by nonsense or frameshift alterations in the coding sequence or by splice variants.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>In itself, loss-of-function mutations was not able to be conferred by nonsense or frameshift alterations in the coding sequence or by splice variants.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="22">
                    <text>In itself, loss-of-function mutations was not conferred by nonsense or frameshift alterations in the coding sequence or by splice variants.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="23">
                    <text>In itself, loss-of-function mutations will not be conferred by nonsense or frameshift alterations in the coding sequence or by splice variants.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="24">
                    <text>In itself, loss-of-function mutations will not have been conferred by nonsense or frameshift alterations in the coding sequence or by splice variants.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="25">
                    <text>In itself, loss-of-function mutations would not be conferred by nonsense or frameshift alterations in the coding sequence or by splice variants.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="26">
                    <text>In itself, nonsense or frameshift alterations in the coding sequence or by splice variants cannot confer loss-of-function mutations.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="27">
                    <text>In itself, nonsense or frameshift alterations in the coding sequence or by splice variants cannot have conferred loss-of-function mutations.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="28">
                    <text>In itself, nonsense or frameshift alterations in the coding sequence or by splice variants could not confer loss-of-function mutations.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="29">
                    <text>In itself, nonsense or frameshift alterations in the coding sequence or by splice variants did not confer loss-of-function mutations.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="30">
                    <text>In itself, nonsense or frameshift alterations in the coding sequence or by splice variants does not confer loss-of-function mutations.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="31">
                    <text>In itself, nonsense or frameshift alterations in the coding sequence or by splice variants is believed not to confer loss-of-function mutations.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="32">
                    <text>In itself, nonsense or frameshift alterations in the coding sequence or by splice variants is not able to confer loss-of-function mutations.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="33">
                    <text>In itself, nonsense or frameshift alterations in the coding sequence or by splice variants may not confer loss-of-function mutations.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="34">
                    <text>In itself, nonsense or frameshift alterations in the coding sequence or by splice variants may not have conferred loss-of-function mutations.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="35">
                    <text>In itself, nonsense or frameshift alterations in the coding sequence or by splice variants might not confer loss-of-function mutations.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="36">
                    <text>In itself, nonsense or frameshift alterations in the coding sequence or by splice variants was believed not to confer loss-of-function mutations.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="37">
                    <text>In itself, nonsense or frameshift alterations in the coding sequence or by splice variants was not able to confer loss-of-function mutations.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="38">
                    <text>In itself, nonsense or frameshift alterations in the coding sequence or by splice variants will not confer loss-of-function mutations.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="39">
                    <text>In itself, nonsense or frameshift alterations in the coding sequence or by splice variants will not have conferred loss-of-function mutations.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="40">
                    <text>In itself, nonsense or frameshift alterations in the coding sequence or by splice variants would not confer loss-of-function mutations.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="41">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), explaining the loss-of-function mutations conferred by nonsense or frameshift alterations in the coding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="42">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), nonsense or frameshift alterations in the coding sequence or by splice variants can confer the loss-of-function mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="43">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), nonsense or frameshift alterations in the coding sequence or by splice variants confer the loss-of-function mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="44">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), nonsense or frameshift alterations in the coding sequence or by splice variants conferred the loss-of-function mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="45">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), nonsense or frameshift alterations in the coding sequence or by splice variants could confer the loss-of-function mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="46">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), nonsense or frameshift alterations in the coding sequence or by splice variants have conferred the loss-of-function mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="47">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), nonsense or frameshift alterations in the coding sequence or by splice variants is able to confer the loss-of-function mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="48">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), nonsense or frameshift alterations in the coding sequence or by splice variants is believed to confer the loss-of-function mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="49">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), nonsense or frameshift alterations in the coding sequence or by splice variants may confer the loss-of-function mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="50">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), nonsense or frameshift alterations in the coding sequence or by splice variants might confer the loss-of-function mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="51">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), nonsense or frameshift alterations in the coding sequence or by splice variants was able to confer the loss-of-function mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="52">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), nonsense or frameshift alterations in the coding sequence or by splice variants was believed to confer the loss-of-function mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="53">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), nonsense or frameshift alterations in the coding sequence or by splice variants will confer the loss-of-function mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="54">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), nonsense or frameshift alterations in the coding sequence or by splice variants would confer the loss-of-function mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="55">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the loss-of-function mutations can be conferred by nonsense or frameshift alterations in the coding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="56">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the loss-of-function mutations could be conferred by nonsense or frameshift alterations in the coding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="57">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the loss-of-function mutations has been conferred by nonsense or frameshift alterations in the coding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="58">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the loss-of-function mutations is able to be conferred by nonsense or frameshift alterations in the coding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="59">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the loss-of-function mutations is believed to be conferred by nonsense or frameshift alterations in the coding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="60">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the loss-of-function mutations is conferred by nonsense or frameshift alterations in the coding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="61">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the loss-of-function mutations may be conferred by nonsense or frameshift alterations in the coding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="62">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the loss-of-function mutations might be conferred by nonsense or frameshift alterations in the coding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="63">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the loss-of-function mutations was able to be conferred by nonsense or frameshift alterations in the coding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="64">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the loss-of-function mutations was believed to be conferred by nonsense or frameshift alterations in the coding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="65">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the loss-of-function mutations was conferred by nonsense or frameshift alterations in the coding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="66">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the loss-of-function mutations will be conferred by nonsense or frameshift alterations in the coding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="67">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the loss-of-function mutations would be conferred by nonsense or frameshift alterations in the coding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="68">
                    <text>loss-of-function mutations in a tolC-deficient strain can be conferred by nonsense or frameshift alterations in the coding sequence or by splice variants.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="69">
                    <text>loss-of-function mutations in a tolC-deficient strain has been conferred by nonsense or frameshift alterations in the coding sequence or by splice variants.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="70">
                    <text>loss-of-function mutations in a tolC-deficient strain is able to be conferred by nonsense or frameshift alterations in the coding sequence or by splice variants.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="71">
                    <text>loss-of-function mutations in a tolC-deficient strain is conferred by nonsense or frameshift alterations in the coding sequence or by splice variants.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="72">
                    <text>loss-of-function mutations in a tolC-deficient strain may have been conferred by nonsense or frameshift alterations in the coding sequence or by splice variants.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
                <example src="REPLACE" no="73">
                    <text>loss-of-function mutations in a tolC-deficient strain was conferred by nonsense or frameshift alterations in the coding sequence or by splice variants.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
